Brazil’s Health Regulatory Agency (Anvisa) approved on Monday the use of the drug Sunlenca (lenacapavir) for HIV-1 prevention as pre-exposure prophylaxis (PrEP), Agencia Brasil reported.
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
